The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...

Targeted therapies directed at specific driver oncogenes have improved outcomes for individuals with advanced non-small cell lung cancer (NSCLC). Approximately 5% of lung adenocarcinomas, the most ...

An agent that may fulfill these requirements is the glycan-binding protein Galectin-9 (Gal-9). Indeed, treatment with Gal-9 reduced total cell counts and cell viability of various B cell NHL cell ...

WEDNESDAY, June 25, 2025 (HealthDay News) — For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell lymphoma ...

WEDNESDAY, June 25, 2025 (HealthDay News) -- For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell ...

The 14-gene assay identified patients with molecular high risk who benefitted from adjuvant chemotherapy. Use of the assay to determine eligibility for adjuvant therapy in stage IA–IIA non-squamous ...

Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching The following represents disclosure information ...